Mosaic Biosciences Launches Tessaic Nano, an In Vitro VHH Antibody Library for Rapid Nanobody Discovery

Fully human synthetic single-domain library expands Mosaic's VHH discovery capabilities alongside its in vivo partnership with Abkyu



Tessaic Nano Library

BOULDER, CO, UNITED STATES, September 8, 2026 /EINPresswire.com/ -- Mosaic Biosciences, a biologics discovery CRO focused on antibody and protein engineering, today announced the launch of Tessaic(TM) Nano, a fully human synthetic in vitro VHH library designed to accelerate nanobody discovery for clients across therapeutic, diagnostic, and research applications.

Tessaic Nano is the first library released under Mosaic's Tessaic antibody library system, which also includes Tessaic Fab, a set of curated Fab-format libraries, near launch. The Nano library gives clients a fast, fully in-house route to single-domain candidates, requiring no humanization and no camelid immunization step.

“Clients are increasingly running in vitro and in vivo VHH discovery in parallel to de-risk timelines and compare candidate profiles,” said Tracey Mullen, Chief Strategy Officer at Mosaic Biosciences. “Tessaic Nano gives us a rapid, fully human option built entirely in-house, and it complements the work we do with Abkyu on the in vivo side. Together, these options let clients choose the discovery route that fits their program, or run both.”

Because Tessaic Nano is a fully human synthetic library, candidates emerge without the humanization step required for camelid-derived VHHs, shortening development timelines for programs headed toward the clinic.

Along with donor derived CDRH3 diversity, Tessaic Nano incorporates curated diversity across CDRH1 and CDRH2, informed by internal repertoire analysis of which diversity placements have produced the strongest hit rates. Diversity is sourced from immune material captured and processed entirely in-house, and germlines are selected using literature-backed developability

and pairing data, with liability filtering built into the design from the outset rather than addressed downstream.

The library launch follows Mosaic's recent preferred partnership with Abkyu, a Boston-based in vivo VHH discovery specialist, giving Mosaic clients access to both in vitro and in vivo single-domain discovery routes under one program.

Tessaic Nano is available now. Mosaic will be introducing the library at upcoming industry events, including Festival of Biologics Basel (October 13–15) and PEGS Europe (November 16–19).

About Mosaic Biosciences

Mosaic Biosciences is a Boulder, Colorado-based biologics discovery CRO offering integrated antibody discovery, protein engineering, and non-antibody therapeutic capabilities. Mosaic partners with biotech and pharma clients to deliver decision-grade candidates with predictable outcomes, from early discovery through developability.

Chrissy Conti
Mosaic Biosciences
chrissy@mosaicbio.com

This press release can be viewed online at: https://www.einpresswire.com/article/940537878

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.